| Genomic analyses identify molecular subtypes of pancreatic cancer P Bailey, DK Chang, K Nones, AL Johns, AM Patch, MC Gingras, ... Nature 531 (7592), 47-52, 2016 | 3531 | 2016 |
| Whole genomes redefine the mutational landscape of pancreatic cancer N Waddell, M Pajic, AM Patch, DK Chang, KS Kassahn, P Bailey, ... Nature 518 (7540), 495-501, 2015 | 2809 | 2015 |
| Pan-cancer analysis of whole genomes Nature 578 (7793), 82-93, 2020 | 2540* | 2020 |
| Pancreatic cancer genomes reveal aberrations in axon guidance pathway genes AV Biankin, N Waddell, KS Kassahn, MC Gingras, LB Muthuswamy, ... Nature 491 (7424), 399-405, 2012 | 2299 | 2012 |
| Prognostic and Clinicopathologic Associations of Oncogenic BRAF in Metastatic Melanoma GV Long, AM Menzies, AM Nagrial, LE Haydu, AL Hamilton, GJ Mann, ... Journal of Clinical Oncology 29 (10), 1239-1246, 2011 | 1331 | 2011 |
| Whole-genome landscape of pancreatic neuroendocrine tumours A Scarpa, DK Chang, K Nones, V Corbo, AM Patch, P Bailey, RT Lawlor, ... Nature 543 (7643), 65-71, 2017 | 949 | 2017 |
| Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: results from the KEYNOTE‐158 and KEYNOTE‐028 studies SA Piha‐Paul, DY Oh, M Ueno, D Malka, HC Chung, A Nagrial, RK Kelley, ... International journal of cancer 147 (8), 2190-2198, 2020 | 435 | 2020 |
| The prognostic and predictive value of serum CA19. 9 in pancreatic cancer JL Humphris, DK Chang, AL Johns, CJ Scarlett, M Pajic, MD Jones, ... Annals of oncology 23 (7), 1713-1722, 2012 | 365 | 2012 |
| Transient tissue priming via ROCK inhibition uncouples pancreatic cancer progression, sensitivity to chemotherapy, and metastasis C Vennin, VT Chin, SC Warren, MC Lucas, D Herrmann, A Magenau, ... Science translational medicine 9 (384), eaai8504, 2017 | 262 | 2017 |
| Precision medicine for advanced pancreas cancer: the individualized molecular pancreatic cancer therapy (IMPaCT) trial LA Chantrill, AM Nagrial, C Watson, AL Johns, M Martyn-Smith, ... Clinical cancer research 21 (9), 2029-2037, 2015 | 246 | 2015 |
| Hypermutation in pancreatic cancer JL Humphris, AM Patch, K Nones, PJ Bailey, AL Johns, S McKay, ... Gastroenterology 152 (1), 68-74. e2, 2017 | 225 | 2017 |
| Evaluation of combination nivolumab and ipilimumab immunotherapy in patients with advanced biliary tract cancers: subgroup analysis of a phase 2 nonrandomized clinical trial O Klein, D Kee, A Nagrial, B Markman, C Underhill, M Michael, L Jackett, ... JAMA oncology 6 (9), 1405-1409, 2020 | 215 | 2020 |
| First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small-cell lung cancer☆ J Niu, C Maurice-Dror, DH Lee, DW Kim, A Nagrial, M Voskoboynik, ... Annals of Oncology 33 (2), 169-180, 2022 | 204 | 2022 |
| Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer B Lee, L Lipton, J Cohen, J Tie, AA Javed, L Li, D Goldstein, M Burge, ... Annals of Oncology 30 (9), 1472-1478, 2019 | 197 | 2019 |
| Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater DK Chang, NB Jamieson, AL Johns, CJ Scarlett, M Pajic, A Chou, ... Journal of clinical oncology 31 (10), 1348-1356, 2013 | 195 | 2013 |
| Chemotherapy and radiotherapy for advanced pancreatic cancer V Chin, A Nagrial, K Sjoquist, CA O'Connor, L Chantrill, AV Biankin, ... Cochrane Database of Systematic Reviews, 2018 | 173 | 2018 |
| Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209-538 clinical trial for rare cancers O Klein, D Kee, B Markman, M Michael, C Underhill, MS Carlino, L Jackett, ... Clinical Cancer Research 26 (17), 4454-4459, 2020 | 155 | 2020 |
| Pembrolizumab (pembro) for advanced biliary adenocarcinoma: Results from the KEYNOTE-028 (KN028) and KEYNOTE-158 (KN158) basket studies. YJ Bang, M Ueno, D Malka, HC Chung, A Nagrial, RK Kelley, ... Journal of Clinical Oncology 37 (15_suppl), 4079-4079, 2019 | 147 | 2019 |
| Clinical and molecular characterization of HER2amplified-pancreatic cancer A Chou, N Waddell, MJ Cowley, AJ Gill, DK Chang, AM Patch, K Nones, ... Genome medicine 5, 1-11, 2013 | 147 | 2013 |
| Tailored first-line and second-line CDK4-targeting treatment combinations in mouse models of pancreatic cancer A Chou, D Froio, AM Nagrial, A Parkin, KJ Murphy, VT Chin, D Wohl, ... Gut 67 (12), 2142-2155, 2018 | 132 | 2018 |
Venessa ChinGarvan Institute of Medical ResearchEmail verificata su garvan.org.au